On September 25, 2025, Jay Olson from Oppenheimer set a price target of $30 for Immuneering Corporation (NASDAQ:IMRX). At the time, the stock was trading at $9.23, suggesting a potential upside of about 25%. Immuneering is a clinical-stage oncology company focused on developing treatments for cancer. The company is listed on the NASDAQ exchange.
Immuneering recently announced the pricing of its underwritten public offering, offering 18.96 million shares of Class A common stock at $9.23 per share. This matches the last reported sale price on the Nasdaq Global Market as of September 24, 2025. The offering is expected to generate approximately $175 million in gross proceeds, before accounting for underwriting discounts, commissions, and other expenses.
Additionally, Immuneering has provided underwriters with a 30-day option to purchase up to an additional 2.84 million shares at the same public offering price. Concurrently, the company has arranged a $25 million private placement of Class A common stock with Sanofi. This strategic move aims to bolster the company's financial position and support its ongoing research and development efforts.
Despite these developments, the stock for IMRX is currently priced at $8, reflecting a decrease of approximately 13.33% with a drop of $1.23. During the day, the stock has fluctuated between a low of $7.63 and a high of $9.60. Over the past year, the stock has reached a high of $10.08 and a low of $1.10, indicating significant volatility.
IMRX has a market capitalization of approximately $290.42 million, with a trading volume of 13,719,027 shares for the day. The company's recent financial activities, including the public offering and private placement, are crucial steps in its growth strategy as it continues to navigate the competitive oncology market.
